In vivo imaging of cancer biomarkers using activatable molecular probes

Drew R. Elias, Daniel L J Thorek, Antony K. Chen, Julie Czupryna, Andrew Tsourkas

Research output: Contribution to journalArticle

Abstract

With the continued advancements in cellular and molecular biology, especially in the areas of genomics, proteomics and metabolomics, the scientific research community is gaining ground in uncovering the tortuous details associated with cancer. Molecular imaging has undergone a similar progression and is showing promise as a future method to aid in the early detection of malignancies, locating metastatic disease, staging tumors, evaluating the availability of therapeutic targets, and monitoring the efficacy of treatment. A subset of molecular imaging contrast agents known as "activatable molecular probes" has generated a particularly high level of excitement in the imaging community. Activatable molecular probes are designed to elicit a detectable change in signal upon enzymatic activity or in response to specific biomolecular interactions. In many cases, these unique characteristics allow for very high signal-to-background ratios compared with conventional targeted contrast agents and they open up the possibility of imaging intracellular targets. In this review, we will discuss some of the activatable probes recently developed for optical and magnetic resonance imaging platforms and their use in the visualization of cancer biomarkers in vivo.

Original languageEnglish (US)
Pages (from-to)287-305
Number of pages19
JournalCancer Biomarkers
Volume4
Issue number6
StatePublished - 2008
Externally publishedYes

Fingerprint

Molecular Probes
Molecular Imaging
Tumor Biomarkers
Contrast Media
Metabolomics
Neoplasm Staging
Genomics
Proteomics
Cell Biology
Molecular Biology
Neoplasms
Magnetic Resonance Imaging
Research
Therapeutics

Keywords

  • Activatable probes
  • Molecular beacons
  • Molecular imaging
  • Molecular probes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Genetics

Cite this

Elias, D. R., Thorek, D. L. J., Chen, A. K., Czupryna, J., & Tsourkas, A. (2008). In vivo imaging of cancer biomarkers using activatable molecular probes. Cancer Biomarkers, 4(6), 287-305.

In vivo imaging of cancer biomarkers using activatable molecular probes. / Elias, Drew R.; Thorek, Daniel L J; Chen, Antony K.; Czupryna, Julie; Tsourkas, Andrew.

In: Cancer Biomarkers, Vol. 4, No. 6, 2008, p. 287-305.

Research output: Contribution to journalArticle

Elias, DR, Thorek, DLJ, Chen, AK, Czupryna, J & Tsourkas, A 2008, 'In vivo imaging of cancer biomarkers using activatable molecular probes', Cancer Biomarkers, vol. 4, no. 6, pp. 287-305.
Elias DR, Thorek DLJ, Chen AK, Czupryna J, Tsourkas A. In vivo imaging of cancer biomarkers using activatable molecular probes. Cancer Biomarkers. 2008;4(6):287-305.
Elias, Drew R. ; Thorek, Daniel L J ; Chen, Antony K. ; Czupryna, Julie ; Tsourkas, Andrew. / In vivo imaging of cancer biomarkers using activatable molecular probes. In: Cancer Biomarkers. 2008 ; Vol. 4, No. 6. pp. 287-305.
@article{df5f5bb8673349dbbacade0f9ffdf418,
title = "In vivo imaging of cancer biomarkers using activatable molecular probes",
abstract = "With the continued advancements in cellular and molecular biology, especially in the areas of genomics, proteomics and metabolomics, the scientific research community is gaining ground in uncovering the tortuous details associated with cancer. Molecular imaging has undergone a similar progression and is showing promise as a future method to aid in the early detection of malignancies, locating metastatic disease, staging tumors, evaluating the availability of therapeutic targets, and monitoring the efficacy of treatment. A subset of molecular imaging contrast agents known as {"}activatable molecular probes{"} has generated a particularly high level of excitement in the imaging community. Activatable molecular probes are designed to elicit a detectable change in signal upon enzymatic activity or in response to specific biomolecular interactions. In many cases, these unique characteristics allow for very high signal-to-background ratios compared with conventional targeted contrast agents and they open up the possibility of imaging intracellular targets. In this review, we will discuss some of the activatable probes recently developed for optical and magnetic resonance imaging platforms and their use in the visualization of cancer biomarkers in vivo.",
keywords = "Activatable probes, Molecular beacons, Molecular imaging, Molecular probes",
author = "Elias, {Drew R.} and Thorek, {Daniel L J} and Chen, {Antony K.} and Julie Czupryna and Andrew Tsourkas",
year = "2008",
language = "English (US)",
volume = "4",
pages = "287--305",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "IOS Press",
number = "6",

}

TY - JOUR

T1 - In vivo imaging of cancer biomarkers using activatable molecular probes

AU - Elias, Drew R.

AU - Thorek, Daniel L J

AU - Chen, Antony K.

AU - Czupryna, Julie

AU - Tsourkas, Andrew

PY - 2008

Y1 - 2008

N2 - With the continued advancements in cellular and molecular biology, especially in the areas of genomics, proteomics and metabolomics, the scientific research community is gaining ground in uncovering the tortuous details associated with cancer. Molecular imaging has undergone a similar progression and is showing promise as a future method to aid in the early detection of malignancies, locating metastatic disease, staging tumors, evaluating the availability of therapeutic targets, and monitoring the efficacy of treatment. A subset of molecular imaging contrast agents known as "activatable molecular probes" has generated a particularly high level of excitement in the imaging community. Activatable molecular probes are designed to elicit a detectable change in signal upon enzymatic activity or in response to specific biomolecular interactions. In many cases, these unique characteristics allow for very high signal-to-background ratios compared with conventional targeted contrast agents and they open up the possibility of imaging intracellular targets. In this review, we will discuss some of the activatable probes recently developed for optical and magnetic resonance imaging platforms and their use in the visualization of cancer biomarkers in vivo.

AB - With the continued advancements in cellular and molecular biology, especially in the areas of genomics, proteomics and metabolomics, the scientific research community is gaining ground in uncovering the tortuous details associated with cancer. Molecular imaging has undergone a similar progression and is showing promise as a future method to aid in the early detection of malignancies, locating metastatic disease, staging tumors, evaluating the availability of therapeutic targets, and monitoring the efficacy of treatment. A subset of molecular imaging contrast agents known as "activatable molecular probes" has generated a particularly high level of excitement in the imaging community. Activatable molecular probes are designed to elicit a detectable change in signal upon enzymatic activity or in response to specific biomolecular interactions. In many cases, these unique characteristics allow for very high signal-to-background ratios compared with conventional targeted contrast agents and they open up the possibility of imaging intracellular targets. In this review, we will discuss some of the activatable probes recently developed for optical and magnetic resonance imaging platforms and their use in the visualization of cancer biomarkers in vivo.

KW - Activatable probes

KW - Molecular beacons

KW - Molecular imaging

KW - Molecular probes

UR - http://www.scopus.com/inward/record.url?scp=58149385769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149385769&partnerID=8YFLogxK

M3 - Article

C2 - 19126958

AN - SCOPUS:58149385769

VL - 4

SP - 287

EP - 305

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 6

ER -